Abstract: A crystal of a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R1 is a hydrogen atom or a hydroxy group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group.

Abstract: A crystal of a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R1 is a hydrogen atom or a hydroxy group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.

Abstract: A power generation switch apparatus including multiple switch keys, a power generation apparatus that is driven to perform power generation by an operation force applied to the multiple switch keys, multiple switches being supplied with an electric power generated by the power generation apparatus and performing a switching movement by an operation of the multiple switch keys, and a switch signal transmission circuit being driven by the electric power from the power generation apparatus and outputting multiple switch signals that are different from each other in correspondence with the switching movement of the multiple switches.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract: A power generation apparatus includes an operation member that has a first operation part or a second operation part operated upon power generation; a power generation part that generates an induced electromotive force upon being driven by a slide member that moves in a first direction or a second direction; first and second elastic units that accumulate an elastic force; a first connection release mechanism that prompts the first elastic unit to accumulate elastic force when the first operation part is operated and allows the elastic force to be output to move the slide member in the second direction when accumulation is completed; and a second connection release mechanism that prompts the second elastic unit to accumulate the elastic force when the second operation part is operated and allows the elastic force to be output to move the slide member in the first direction when accumulation is completed.

Abstract: A power generation switch apparatus including multiple switch keys, a power generation apparatus that is driven to perform power generation by an operation force applied to the multiple switch keys, multiple switches being supplied with an electric power generated by the power generation apparatus and performing a switching movement by an operation of the multiple switch keys, and a switch signal transmission circuit being driven by the electric power from the power generation apparatus and outputting multiple switch signals that are different from each other in correspondence with the switching movement of the multiple switches.

Abstract: A power generation apparatus includes an operation member that has a first operation part or a second operation part operated upon power generation; a power generation part that generates an induced electromotive force upon being driven by a slide member that moves in a first direction or a second direction; first and second elastic units that accumulate an elastic force; a first connection release mechanism that prompts the first elastic unit to accumulate elastic force when the first operation part is operated and allows the elastic force to be output to move the slide member in the second direction when accumulation is completed; and a second connection release mechanism that prompts the second elastic unit to accumulate the elastic force when the second operation part is operated and allows the elastic force to be output to move the slide member in the first direction when accumulation is completed.

Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].

Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].

Abstract: It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect.

Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].

Abstract: It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect.

Abstract: A process for producing a cyclopropylphenol represented by of formula (10): wherein R1, R2, R3 and R4 each may represent a hydrogen; Z represents a hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or phenyl; and Y1, Y2 and Y3 each may represent a hydrogen; by reacting a compound of formula (7): wherein X represents a halogen; and V represents a hydrogen or —W—R5, with a metal, metal salt or organometallic compound of formula (8): M2 to obtain a compound of formula (9): and obtaining a compound of formula (10) by hydrolysis in the case wherein V represents —W—R5, wherein W is CO, SO or SO2 and R5 is alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, phenyl, alkoxy or haloalkoxy.

Abstract: The present invention is to provide a method for forming a multi-layer coating film, which can combine a pre-treating step conducted for a metal substrate, before electrodeposition coating, and an electrodeposition coating step. The method comprises: a step of dipping a material to be coated in an aqueous coating composition comprising (A) a rare earth metal compound, (B) a base resin having a cationic group, and (C) a curing agent, wherein a content of the rare earth metal compound (A) in the aqueous coating composition is limited to specific range; a pre-treating step of applying a voltage of less than 50 V in the aqueous coating composition, wherein the material to be coated is used as a cathode; and an electrodeposition coating of applying a voltage of 50 to 450 V in the aqueous coating composition, wherein the material to be coated is used as a cathode.

Abstract: The present invention relates to a composite chemical conversion coating film containing a crystalline continuous coating film that is formed on a metal substrate. The present invention also relates to a process for forming a multiple layered coating film including (A) the first step of immersing an untreated metal substrate in an aqueous solution containing nitrate of a rare earth metal and forming a crystalline continuous coating film containing a rare earth metal compound with a deposition amount of 1 mg/m2 at lower limit and 110 mg/m2 at upper limit by cathode electrolysis and (B) the second step of coating an electrodeposition coating composition containing an organic acid or inorganic acid salt of a rare earth metal by cathode electrodeposition.

Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].

Abstract: A process for producing a cyclopropylphenol represented by of formula (10): wherein R1, R2, R3 and R4 each may represent a hydrogen; Z represents a hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or phenyl; and Y1, Y2 and Y3 each may represent a hydrogen; by reacting a compound of formula (7): wherein X represents a halogen; and V represents a hydrogen or —W—R5, with a metal, metal salt or organometallic compound of formula (8): M2 to obtain a compound of formula (9): and obtaining a compound represented by general of formula (10) by hydrolysis in the case wherein V represents —W—R5, wherein W is CO, SO or SO2 and R5 is alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, phenyl, alkoxy or haloalkoxy.